{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:26:22Z","timestamp":1791116782297,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.annder.2014.03.009","type":"journal-article","created":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T12:01:04Z","timestamp":1397390464000},"page":"354-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Toxicit\u00e9 endobuccale des th\u00e9rapies cibl\u00e9es anticanc\u00e9reuses"],"prefix":"10.1016","volume":"141","author":[{"given":"V.","family":"Sibaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Boralevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vigarios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-C.","family":"Fricain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2014.03.009_bib0005","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.annder.2013.02.031","article-title":"Effets ind\u00e9sirables cutan\u00e9s des inhibiteurs de BRAF\u00a0: revue syst\u00e9matique","volume":"140","author":"Sibaud","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2014.03.009_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.seminoncol.2012.01.009","article-title":"Advances in the management of cutaneous toxicities of targeted therapies","volume":"39","author":"Robert","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","article-title":"Dermatologic symptoms associated with the multikinase inhibitor sorafenib","volume":"60","author":"Robert","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2014.03.009_bib0020","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.oraloncology.2011.03.028","article-title":"Oral complications of targeted cancer therapies: a narrative literature review","volume":"47","author":"Watters","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0030","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1634\/theoncologist.2012-0421","article-title":"Geographic tongue induced by angiogenesis inhibitors: in reply","volume":"18","author":"Rosen","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2014.03.009_bib0035","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.oraloncology.2011.08.009","article-title":"Clinical presentation and management of mTOR inhibitor-associated stomatitis","volume":"47","author":"De Oliveira","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","article-title":"Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients","volume":"116","author":"Sonis","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0045","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejca.2011.11.028","article-title":"The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis","volume":"48","author":"Gomez-Fernandez","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1634\/theoncologist.2011-0111","article-title":"Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review","volume":"17","author":"Boers-Doets","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2014.03.009_bib0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2010-0263","article-title":"Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities","volume":"16","author":"Kollmannsberger","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2014.03.009_bib0060","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.22484","article-title":"Updated clinical practice guidelines for the prevention and treatment of mucositis","volume":"109","author":"Keefe","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0065","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/annonc\/mdr391","article-title":"Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines","volume":"22","author":"Peterson","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1470-2045(05)01735-3","article-title":"Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea","volume":"6","author":"Sharma","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0075","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.soncn.2011.08.001","article-title":"Clinical update: prevention and management of oral mucositis in patients with cancer","volume":"27","author":"Eilers","year":"2011","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.annder.2014.03.009_bib0080","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0085","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2008.09.007","article-title":"High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes","volume":"90","author":"Giro","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0090","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0095","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2014.03.009_bib0100","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/cncr.24120","article-title":"Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy","volume":"115","author":"Tejwani","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0105","first-page":"3243","article-title":"Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis","volume":"21","author":"Elting","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0110","first-page":"509","article-title":"A proposed EGFR inhibitor adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0115","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2014.03.009_bib0120","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.oraloncology.2011.07.023","article-title":"Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma","volume":"47","author":"Pryor","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0125","series-title":"Skin side effects induced by targeted anticancer therapies: a new dermatology","first-page":"125","article-title":"Oral toxicity of targeted anticancer therapies","author":"Chaux-Bodard","year":"2010"},{"key":"10.1016\/j.annder.2014.03.009_bib0130","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.radonc.2008.09.018","article-title":"Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer","volume":"90","author":"Pryor","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.oraloncology.2012.11.008","article-title":"A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients","volume":"49","author":"Martins","year":"2013","journal-title":"Oral Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","article-title":"Common toxicities of mammalian target of rapamycin inhibitors","volume":"6","author":"Soefje","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0145","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","article-title":"Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma","volume":"47","author":"Porta","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0150","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10549-013-2630-y","article-title":"Everolimus: side effect profile and management of toxicities in breast cancer","volume":"140","author":"Paplomata","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annder.2014.03.009_bib0155","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Amitay-Laish","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.annder.2014.03.009_bib0160","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(01)06903-3","article-title":"Imatinib for chronic myeloid leukaemia: a NICE mess","volume":"358","author":"Lim","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2014.03.009_bib0165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1684\/ejd.2010.0818","article-title":"Oral lichenoid eruption associated with imatinib treatment","volume":"20","author":"G\u00f3mez Fern\u00e1ndez","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2014.03.009_bib0170","first-page":"465","article-title":"Skin and oral lesions associated to imatinib mesylate therapy","volume":"17","author":"Basso","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D319T833JH","article-title":"Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review","volume":"14","author":"Wahiduzzaman","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2014.03.009_bib0180","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1365-4632.2006.03171.x","article-title":"Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases","volume":"45","author":"Pascual","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2014.03.009_bib0185","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/09546630410015556","article-title":"Oral lichenoid eruption secondary to imatinib (Glivec)","volume":"15","author":"Ena","year":"2004","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.annder.2014.03.009_bib0190","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.annder.2013.01.442","article-title":"Anomalies pigmentaires induites par les traitements anticanc\u00e9reux. Deuxi\u00e8me partie\u00a0: les th\u00e9rapies cibl\u00e9es","volume":"140","author":"Sibaud","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2014.03.009_bib0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D3498194BX","article-title":"Oral melanosis after tyrosine kinase inhibition with imatinib for chronic myelogenous leukemia: report of a case and review of the literature","volume":"17","author":"Wong","year":"2011","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2014.03.009_bib0200","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3109\/10428194.2012.702904","article-title":"Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT","volume":"54","author":"Khoo","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annder.2014.03.009_bib0205","first-page":"764","article-title":"Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy","volume":"129","author":"Yu","year":"2012","journal-title":"Tex Dent J"},{"key":"10.1016\/j.annder.2014.03.009_bib0210","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.tripleo.2010.11.006","article-title":"Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases","volume":"111","author":"Mattsson","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.annder.2014.03.009_bib0215","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12105-011-0325-4","article-title":"Mucosal pigmentation caused by imatinib: report of three cases","volume":"6","author":"Li","year":"2012","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.annder.2014.03.009_bib0220","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.tripleo.2011.04.003","article-title":"Are we ready to blame imatinib for palatal pigmentation? Reply","volume":"112","author":"Mattson","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.annder.2014.03.009_bib0225","first-page":"1062","article-title":"Pigmentary changes in a patient treated with imatinib","volume":"10","author":"Balagula","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.annder.2014.03.009_bib0230","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-3083.2008.02706.x","article-title":"Imatinib-associated hyperpigmentation, a side effect that should be recognized","volume":"23","author":"Mcpherson","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2014.03.009_bib0235","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.eururo.2011.01.002","article-title":"Toxicities of targeted therapy and their management in kidney cancer","volume":"59","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.annder.2014.03.009_bib0240","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.ejca.2012.05.022","article-title":"An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer","volume":"48","author":"Powles","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0245","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.annder.2014.03.009_bib0250","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejon.2011.05.001","article-title":"Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group","volume":"16","author":"Edmonds","year":"2012","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.annder.2014.03.009_bib0255","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastroinstetinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3\u00a0trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2014.03.009_bib0260","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","article-title":"Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"161","author":"Lee","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2014.03.009_bib0265","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2407-11-105","article-title":"Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy","volume":"11","author":"Porta","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0270","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1634\/theoncologist.2011-0198","article-title":"Characteristics of oral mucosal events related to bevacizumab treatment","volume":"17","author":"Gavrilovic","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2014.03.009_bib0275","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1634\/theoncologist.2012-0320","article-title":"Geographic tongue induced by angiogenesis inhibitors","volume":"18","author":"Hubiche","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2014.03.009_bib0280","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.annder.2014.03.009_bib0285","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annder.2014.03.009_bib0290","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases","volume":"110","author":"Hoefert","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.annder.2014.03.009_bib0295","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clbc.2011.02.001","article-title":"Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with\/without bevacizumab","volume":"11","author":"Ngamphaiboon","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0300","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.annder.2014.03.009_bib0305","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tripleo.2011.08.024","article-title":"Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2\u00a0cases with clinical implications","volume":"113","author":"Nicolatou-Galitis","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.annder.2014.03.009_bib0310","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials","author":"Qi","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0315","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0320","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2011.06.023","article-title":"Sunitinib related osteonecrosis of jaw: a case report","volume":"113","author":"Fleissig","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.annder.2014.03.009_bib0325","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annder.2014.03.009_bib0330","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0335","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cutaneous side effects associated with the BRAF-inhibitor vemurafenib: a study of 42\u00a0patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2014.03.009_bib0340","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma","volume":"18","author":"Lacouture","year":"2013","journal-title":"Oncologist"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963814001239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963814001239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:01:36Z","timestamp":1758970896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963814001239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0151963814001239"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2014.03.009","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicit\u00e9 endobuccale des th\u00e9rapies cibl\u00e9es anticanc\u00e9reuses","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2014.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}